Propicillin
Chemical compound
- J01CE03 (WHO)
- (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxybutanoyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- 551-27-9 Y
- 92879
- 83843 N
- 8X1R260V33
- C13110 N
- CHEBI:52429 N
- ChEMBL1477112 N
- DTXSID3046291
- Interactive image
- CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)OC3=CC=CC=C3
InChI
- InChI=1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11?,12-,13+,16-/m1/s1 N
- Key:HOCWPKXKMNXINF-XQERAMJGSA-N N
Propicillin is a penicillin.[1] Properties are similar to benzylpenicillin particularly used in streptococcal infections, not resistant to penicillinase. It is acid resistant and can be used orally as the potassium salt.[citation needed]
References
- ^ de Groot AC (2022). "Propicillin". Monographs in Contact Allergy, Volume 4: Systemic Drugs. Boca Raton, Florida: CRC Press, Taylor & Francis Group. p. 823. ISBN 978-1-00-054991-1.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Lipopeptides |
|
---|---|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e